PS1157 EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Authors :: Ulrich Jäger
Matthew S. Davids
Nicole Lamanna
Stephan Stilgenbauer
David T. Weaver
Gabriel Etienne
Paolo Ghia
Stephanie Lustgarten
Árpád Illés
Hagop Youssoufian
Ian W. Flinn
Julio Delgado
Marco Montillo
Bryone J. Kuss
Francesc Bosch
Florence Cymbalista
Constantine S. Tam
Fritz Offner
Source :: HemaSphere. 3:525
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
chemistry.chemical_compound
medicine.medical_specialty
chemistry
business.industry
Internal medicine
Relapsed refractory
medicine
In patient
Hematology
business
Duvelisib
Dose Modification

Tools